Introduction

This page provides a comprehensive analysis of the known insider trading history of Bhaskar Anand. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Bhaskar Anand has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:SMMT / Summit Therapeutics Inc. Chief Accounting Officer 131,426
US:RETA / Reata Pharmaceuticals Inc - Class A SVP, Chief Accounting Officer 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Bhaskar Anand. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Trading History

This table shows the complete list of insider trades made by Bhaskar Anand as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-09-13 2024-09-11 4 SMMT Summit Therapeutics Inc.
Common Stock
A - Award 22,026 131,426 20.13 22.70 499,990 2,983,370
2024-04-04 3 SMMT Summit Therapeutics Inc.
Common Stock
109,400
2023-09-26 2023-09-26 4 RETA REATA PHARMACEUTICALS INC
Class A common stock
D - Sale to Issuer -24,089 0 -100.00
2023-09-07 2023-09-05 4 RETA REATA PHARMACEUTICALS INC
Class A common stock
S - Sale -406 24,089 -1.66 169.20 -68,695 4,075,859
2023-08-17 2023-08-16 4 RETA REATA PHARMACEUTICALS INC
Class A common stock
S - Sale -210 24,495 -0.85 168.42 -35,368 4,125,409
2023-08-17 2023-08-15 4 RETA REATA PHARMACEUTICALS INC
Class A common stock
S - Sale -193 24,705 -0.78 169.06 -32,628 4,176,504
2023-06-16 2023-06-14 4 RETA REATA PHARMACEUTICALS INC
Class A common stock
S - Sale -2,343 24,898 -8.60 102.11 -239,248 2,542,380
2023-06-16 2023-06-14 4 RETA REATA PHARMACEUTICALS INC
Class A common stock
M - Exercise 1,562 27,241 6.08 27.32 42,674 744,224
2023-05-17 2023-05-16 4 RETA REATA PHARMACEUTICALS INC
Class A common stock
S - Sale -136 25,679 -0.53 81.10 -11,030 2,082,664
2023-05-17 2023-05-15 4 RETA REATA PHARMACEUTICALS INC
Class A common stock
S - Sale -950 25,815 -3.55 85.98 -81,684 2,219,659
2023-03-08 2023-03-07 4 RETA REATA PHARMACEUTICALS INC
Class A common stock
S - Sale -165 26,765 -0.61 84.58 -13,956 2,263,784
2023-03-06 2023-03-03 4 RETA REATA PHARMACEUTICALS INC
Class A common stock
S - Sale -820 26,930 -2.95 87.47 -71,725 2,355,567
2023-03-02 2023-03-01 4 RETA REATA PHARMACEUTICALS INC
Class A common stock
A - Award 3,000 27,750 12.12
2023-01-04 2023-01-03 4 RETA REATA PHARMACEUTICALS INC
Class A common stock
A - Award 8,250 24,750 50.00
2022-01-05 2022-01-03 4 RETA REATA PHARMACEUTICALS INC
Employee Stock Option (right to buy)
A - Award 25,000 25,000
2022-01-05 2022-01-03 4 RETA REATA PHARMACEUTICALS INC
Class A common stock
A - Award 12,500 16,500 312.50
2021-11-15 3 RETA REATA PHARMACEUTICALS INC
Class A common stock
4,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)